FDA lifts hold on one of two Phase 3 gene editing studies by Intellia
Lei Lei Wu / endpoints - The FDA has allowed Intellia Therapeutics to resume one of its two pivotal trials of a gene editing therapy for transthyretin amyloidosis, which is a disease caused by misfolded proteins. Intellia
AI Summary: U.S. regulators have just cleared Intellia Therapeutics’ Phase 3 study of a gene‐editing therapy intended to treat a genetic nerve disorder, effectively rescinding a clinical hold. This development opens the door to renewed patient enrolment and further evaluation of the treatment’s safety and effectiveness.
Related Stories
FDA rejects Corcept’s cortisol modulator triggering setback / 6 months
FDA approves Rucaparib for advanced prostate cancer / 6 months
FDA approves first gene therapy for Wiskott‐Aldrich syndrome / 6 months
FDA Approves Novartis’ Itvisma Gene Therapy for SMA Across Age Groups / 7 months
FDA Approves Ziftomenib for AML Treatment / 7 months
FDA updates Sarepta gene therapy label with severe warnings / 7 months
FDA clears AstraZeneca’s new blood-pressure drug baxdrostat / 7 wks
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Infectious Disease, Reproductive Health, FDA, Clinical Trials and look for the RSS link.
StackHealth Time Machine